Introduction {#sec1-1}
============

Cardiovascular disease accounts for almost half of the deaths of patients with end-stage renal disease (ESRD).\[[@ref1][@ref2][@ref3][@ref4]\] Causes of cardiovascular mortality in patients with chronic kidney disease (CKD) and ESRD include both nontraditional risk factors such as altered calcium-phosphorus metabolism, inflammation, oxidative stress, as well as traditional risk factors such as hypertension, smoking, diabetes, and dyslipidemia.\[[@ref5]\] The overall prevalence of coronary artery disease (CAD) in chronic dialysis patients ranges between 30% and 60% in various studies.\[[@ref6][@ref7][@ref8][@ref9][@ref10][@ref11]\] The gold standard test to diagnose CAD is coronary angiography (CAG), which is invasive. Although, in general population, computerized tomography CAG is a valid noninvasive alternative, especially in low-probability cases, this is not reliable in Stage 5 CKD patients due to altered bone mineral metabolism.

The prevalence of CAD in dialysis patients had been assessed by CAG in various studies. However, all these studies were carried out in chronic hemodialysis (HD) patients; only one study assessed prevalence of CAD at the initiation of HD, but sample size was very small (*n* = 24).\[[@ref12]\] Knowledge about CAD at the initiation of dialysis is important as cardiovascular system (CVS) involvement is the most common cause of death in HD patients and better screening strategies can be employed to decrease CVS-related mortality.

The aim of the present study was to assess the prevalence of CAD in ESRD patients at the initiation of HD and risk factors for CAD in this population.

Materials and Methods {#sec1-2}
=====================

This was a single-center retrospective study to assess the prevalence of CAD in ESRD patients at the initiation of HD and the risk factors for CAD in this population. Medical records of eligible patients who underwent CAG between August 1, 2013, and May 31, 2016, were analyzed. All these patients were essentially covered by insurance and protocol CAG was performed in all these patients at the time of initiation of HD irrespective of the presence or absence of CAD symptoms.

Inclusion criteria were age \>18 years and those who were subjected to CAG within 2 weeks of initiation of HD. Exclusion criteria were previous history of CAD, and CAG performed in chronic HD patients. Data regarding age, sex, history of smoking, symptoms of CAD, and diabetic nephropathy (DN) were obtained. Laboratory parameters such as lipid profile, calcium, phosphorous, Ca × PO~4~ product, high-sensitivity C-reactive protein (hs-CRP), resting electrocardiogram (ECG), and echocardiography were noted. DN was diagnosed when it was biopsy proven or when patient had diabetes mellitus of more than 10-year duration with typical DN clinical picture.

The resting ECG was recorded as abnormal if there was evidence of pathological Q-waves, left ventricular hypertrophy, ST depression or elevation of \>1 mm, T-wave inversion, or bundle branch block. Regional wall motion abnormality (RWMA) and global hypokinesia were documented in echocardiography. In CAG, we evaluated the presence or absence of CAD, number of vessels involved among left anterior descending artery (LAD), left circumflex artery (LCX), and right coronary artery (RCA). Stenosis \>50% was considered as CAD.

According to the findings on CAG, patients were divided into no CAD and CAD groups. Clinical and laboratory parameters between these two groups were analyzed. The approval of the Institutional Ethics Committee was taken before conducting this study.

Statistical analysis {#sec2-1}
--------------------

The clinical characteristics of the patients were presented as mean ± standard deviation for continuous variables and as percentages for categorical variables. Unpaired *t*-test and Chi-square analyses were performed for continuous and categorical variables, respectively. All statistical tests were two-tailed with *P* \< 0.05 to indicate statistical significance.

Results {#sec1-3}
=======

A total of 97 patients were included in the final analysis \[[Table 1](#T1){ref-type="table"}\]. Of the total 44 (45%) patients who were diagnosed with CAD, majority were male patients, i.e., 36 patients in no CAD group and 27 in CAD group. Patients of CAD group were significantly younger with a mean age 50.7 ± 10 years as compared to 55.8 ± 9.3 years in no CAD group (*P* = 0.01). Eleven patients in CAD group and 4 patients in no CAD group were smokers and smoking was associated with an increased risk of CAD (*P* \< 0.01). Symptoms of CAD, which includes chest pain associated with dyspnea, nausea, vomiting, and diaphoresis were not different in two groups; 4 and 8 patients in no CAD and CAD patients. A total of 21 (40%) patients in CAD group and 30 (68%) patients in the no CAD group were diabetics (*P* = 0.007).

###### 

Clinical and laboratory profile of the study population
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Although altered bone mineral metabolism is considered as a nontraditional risk factor for CAD in CKD patients, this was not reflected in our study. Calcium, phosphorous, and Ca × PO~4~ product were not different significantly between two groups. Low total cholesterol and low high-density lipoprotein (HDL) cholesterol were associated with increased risk of CAD (*P* = 0.02 and 0.03, respectively), whereas low-density lipoprotein (LDL), very LDL, and triglycerides were not associated with increased CAD risk. Mean hs-CRP was 11.8920.43 and 38.0663.47 mg/l in no CAD and CAD groups, respectively, and it was associated with an increased risk of CAD (*P* = 0.005). ECG abnormalities were noted in 10 and 14 patients in no CAD and CAD groups, respectively, and ECG changes were not predictive of CAG findings (*P* = NS). Echocardiography abnormalities in the form of RWMAs or global hypokinesia were documented in 2 and 8 patients in no CAD and CAD groups, respectively (*P* = 0.03). Overall, CAD was diagnosed in 44 patients. Details of various number and vessels involved is shown in [Table 2](#T2){ref-type="table"}.
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Coronary angiography findings of the study population
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Discussion {#sec1-4}
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The epidemiology of CAD by CAG was studied in chronic dialysis patients by various authors.\[[@ref6][@ref7][@ref8][@ref9][@ref10][@ref11]\] To the best of our knowledge, patients with ESRD were evaluated at the time of initiation of HD in one study published by Joki *et al*. in 1997.\[[@ref12]\] However, the sample size in this study was small (*n* = 24) and about 50% of patients had chest symptoms suspicious of CAD.

In the present study, the mean age of CAD group was statistically younger than no CAD group, whereas in the study published by Joki *et al*., age was not significantly differed between two groups.\[[@ref12]\] The reason for this difference was not clear, but in Joki *et al*. study, smoking and diabetes were not differed significantly between two groups, whereas in our study smoking, diabetes and hs-CRP levels were significantly higher in CAD group. Whether age itself or other traditional and nontraditional risk factors in this group contributed to CAD should be tested with larger sample size and by regression analysis in further studies.

In the present study, \<20% of the patients had CAD symptoms, and the presence or absence of CAD symptoms is not predictive of CAG findings. This finding is consistent with various studies, in which, compared with the general population, ESRD patients are less likely to have typical CAD symptoms.\[[@ref13][@ref14][@ref15][@ref16][@ref17]\] Almost half of the patients initiated on HD were diagnosed with CAD in the present study, and hence, screening for CAD should be done in all the patients at the time of initiation of HD. However, performing CAG for all patients, especially in asymptomatic patients, is not practical, and hence, some sort of noninvasive method should be considered. Unfortunately, noninvasive methods such as resting ECG, exercise ECG, and pharmacological stress tests are not good predictors of CAD in this special population. Although echocardiography finding of RWMA/global hypokinesia achieved statistical significance between the groups in the present study, only 18% of patients in CAD group had positive findings, which mean that it has a poor correlation. Hence, a reasonable noninvasive alternative is a long-standing due, and at this time, reasonable noninvasive method to screen for CAD would be dobutamine stress echocardiography which has sensitivity and specificity of 75% in dialysis population, though unfortunately, this was not done in the present study population.\[[@ref18]\]

In our study, smoking was significantly associated with an increased risk of CAD and it could be due to the endothelial dysfunction induced by smoking. Increased incidence of cardiac disease due to smoking in HD patients was earlier reported by Di Benedetto *et al*. and Shah *et al*.\[[@ref19][@ref20]\]

DN is associated with an increased risk of CAD as in the general population, and in the present study, 68% of the patients of CAD group patients were diabetics. In the study by Joki *et al*., 73% of the patients were diabetics and 44% of the patients were diabetics in the study conducted by Sharma *et al*.\[[@ref12][@ref18]\]

Low total cholesterol and low HDL cholesterol were associated with an increased risk of CAD. Lower rather than higher cholesterol was significant risk factor for CAD in this population. Malnutrition-induced inflammation which leads to subsequent atherogenesis could be the possible explanation.\[[@ref21]\] Traditionally, hs-CRP is considered as a significant risk factor for CAD in the general population. It is also associated with an increased mortality in the dialysis patients when serum hs-CRP level is \>3 mg/l.\[[@ref22]\] In the present study, the mean hs-CRP level was significantly higher in CAD group and consistent with the earlier literature.

Kidney Disease Outcomes Quality Initiative guidelines recommend that the calcium-phosphate product be maintained below 55 mg/dl^2^ in dialysis patients to prevent vascular calcification, atherosclerosis, and other bone mineral-related diseases. In the present study, calcium, phosphorous, and mean Ca × PO~4~ product in both the groups were in normal range and were not significantly different; better calcium, phosphorous, and Ca × PO~4~ product could be due to the use of noncalcium-containing phosphate binder as cost was not a limiting factor for these insured patients. We did not analyze the role of parathyroid hormone (PTH).

Important limitations of our study were that it was a retrospective analysis and that the present cohort may not reflect the general CKD population as all of them were insured population. Prospective studies involving larger sample size, which represent overall CKD population are needed. The present study only looked at prevalence of CAD and its risk factors at initiation of HD; follow-up data about treatment they received and survival was not analyzed which should be addressed in future studies.

Conclusion {#sec1-5}
==========

At the initiation of dialysis in ESRD patients, CAD was seen in almost half of the patients. DN was a significant risk factor for CAD. Other risk factors for CAD include smoking, low cholesterol, low HDL levels, and high hs-CRP levels.
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